Who
Christopher Patusky
Director
Company insider
Files Form 4 as: Director, United Therapeutics.
In numbers
- Trades disclosed
- 366
- Buys
- 5
- Sells
- 72
- Bought
- $2,422
- Sold
- $29.1M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 26 Jun 2006
- Last trade
- 22 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,380 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,380 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 24 Apr 2026filed 24 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $296K2,910 at $101.80 | filing |
| 24 Apr 2026filed 24 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M2,910 at $569.00 | filing |
| 24 Apr 2026filed 24 Apr 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,910 at $0.00 | filing |
| 24 Apr 2026filed 24 Apr 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,910 at $0.00 | filing |
| 24 Apr 2026filed 24 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $296K2,910 at $101.80 | filing |
| 24 Apr 2026filed 24 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M2,910 at $569.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $102K1,000 at $101.80 | filing |
| 17 Apr 2026filed 17 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $579K1,000 at $578.88 | filing |
| 17 Apr 2026filed 17 Apr 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $102K1,000 at $101.80 | filing |
| 17 Apr 2026filed 17 Apr 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $579K1,000 at $578.88 | filing |
| 15 Dec 2025filed 16 Dec 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 15 Dec 2025filed 16 Dec 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $102K1,000 at $101.80 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026United Therapeutics (NASDAQ: UTHR) general counsel sells 8,300 shares under planUTHR · themarketsdaily.com · 17 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)UTHR · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Christopher Patusky; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.